Pfizer’s Newest Vaccine Plant Has Persistent Mold Issues, History of Recalls
After nearly a decade’s worth of federal inspections, reprimands and corrective action plans, has Pfizer fixed the facility that will be filling vials of its covid vaccine?
Drugs
561-580 of 1,322 results
-
-
KHN’s ‘What the Health?’: Good and Not-So-Good News on Covid
The FDA authorized the emergency use of a one-shot vaccine made by Johnson & Johnson, which could help accelerate the pace of vaccinations to prevent covid-19. But after a dramatic decline, case numbers are again rising, and several states are rolling back public health mitigation efforts. Mary Ellen McIntire of CQ Roll Call, Joanne Kenen of Politico and Sarah Karlin-Smith of the Pink Sheet join KHN’s Julie Rovner to discuss these issues and more. Also this week, Rovner interviews KHN’s Jordan Rau about the latest KHN-NPR “Bill of the Month” episode.
-
Accidentally Trashed, Thawed or Expired: Reports of Covid Vaccine Spoilage
As the speed of covid vaccinations picks up, so do the reports of doses going to waste. Health officials are trying to rein in waste without slowing down vaccinations.
-
In California, Caregivers of People With Disabilities Are Being Turned Away at COVID Vaccine Sites
Parents and caregivers of people with disabilities in California are supposed to be near the front of the line for the covid-19 vaccine. But some are hitting roadblocks at vaccination sites.
-
Why AstraZeneca and J&J’s Vaccines, In Use Elsewhere, Are Still on Hold in America
Covid has pressed the Food and Drug Administration into its fastest vaccine reviews ever — which are still painfully slow, critics say.
-
After Billions of Dollars and Dozens of Wartime Declarations, Why Are Vaccines Still in Short Supply?
The Trump and Biden administrations both imposed wartime production requirements. But industry experts say the vast quantities of raw materials and specialty equipment needed for billions of newfangled vaccines have required herculean logistical efforts.
By Rachana Pradhan and Arthur Allen -
KHN’s ‘What the Health?’: Open Enrollment, One More Time
Keeping a campaign promise, President Joe Biden has reopened enrollment for health coverage under the Affordable Care Act on healthcare.gov — and states that run their own health insurance marketplaces followed suit. At the same time, the Biden administration is moving to revoke the Trump administration’s permission for states to impose work requirements for some adults on the Medicaid health insurance program. Alice Miranda Ollstein of Politico, Kimberly Leonard of Business Insider and Rachel Cohrs of Stat join KHN’s Julie Rovner to discuss these issues and more. Also, Rovner interviews medical student Inam Sakinah, president of the new group Future Doctors in Politics.
-
Can Pfizer and Moderna End the Pandemic by Sharing Their Vaccine Designs? It’s Not that Simple
Industry experts say it’s highly unlikely that dozens of pharmaceutical companies that aren’t already producing covid vaccines stand ready to do so.
-
As Drug Prices Keep Rising, State Lawmakers Propose Tough New Bills to Curb Them
The measures would impose taxes on increases in the price of drugs that don’t reflect improved clinical value and set the rates paid by state-run and commercial health plans to a benchmark based on prices in Canada.
By Harris Meyer -
Farmworker Camps to Urban Tent Cities: Tailoring Vaccine Info to Where It’s Most Needed
Concerns arising in western North Carolina provide a window into the challenges facing health workers across the country as they seek to persuade vulnerable populations to be inoculated against covid.
-
KHN’s ‘What the Health?’: Covid and Kids
Can schools safely reopen before all teachers and staffers are vaccinated against covid? And what’s the best way to communicate that science — and scientific recommendations — change and evolve? Also, get ready for a redo of open enrollment for Affordable Care Act coverage, this time with help and outreach to find those eligible. Margot Sanger-Katz of The New York Times, Alice Miranda Ollstein of Politico and Anna Edney of Bloomberg News join KHN’s Julie Rovner to discuss these issues and more.
-
100 Million Covid Shots in 100 Days Doesn’t Get Us Back to Normal
President Joe Biden’s promise to reach this milestone is an important step forward in vaccine rollout. But it is only the beginning of the sweeping vaccination effort required.
-
When Your Chance for a Covid Shot Comes, Don’t Worry About the Numbers
The Johnson & Johnson vaccine that the FDA cleared Saturday was 66% effective overall in preventing moderate to severe covid, while the Pfizer and Moderna vaccines were more than 90% effective. But the numbers aren’t exactly comparable. And all three shots prevent hospitalization and death.
By Arthur Allen and Liz Szabo -
States Move Ahead With Canada Drug Importation While Awaiting Signal From Biden
As president, Donald Trump encouraged states to bring in drugs from Canada, where prices are cheaper. It’s not clear if the new administration will follow suit.
-
KHN’s ‘What the Health?’: The Long Road to Unwinding Trump Health Policies
President Joe Biden signed a pair of health-related executive orders this week that would, among other things, reopen enrollment under the Affordable Care Act and start to reverse former President Donald Trump’s anti-abortion policies. Meanwhile, Congress remains bogged down with taking up the next round of covid-19 relief. Joanne Kenen of Politico, Mary Ellen McIntire of CQ Roll Call and Shefali Luthra of The 19th join KHN’s Julie Rovner to discuss these issues and more. Plus, for “extra credit,” the panelists recommend their favorite health policy stories of the week they think you should read, too.
-
Remdesivir, Given to Half of Hospitalized Covid Patients in U.S., Is Big Win for Gilead — Boosted by Taxpayers
With U.S. cases skyrocketing, demand for Gilead’s dark horse antiviral is only growing. Biden appointees propose potential legal tactics to tamp down the price for patients.
-
Why Even Presidential Pressure Might Not Get More Vaccine to Market Faster
Even invoking the widely heralded Defense Production Act to pressure drugmakers wouldn’t overcome vast obstacles.
-
Health Issues Carried Weight on the Campaign Trail. What Could Biden Do in His First 100 Days?
KHN has teamed up with PolitiFact to track what becomes of President Joe Biden’s 2020 campaign promises over the next four years. As he moves into the West Wing, what are his chances of making progress on health care?
-
Are Public Health Ads Worth the Price? Not if They’re All About Fear
Public service announcements about drug use or other public health problems often fall short, public health marketing experts say, because they incite people’s worst fears rather than giving people solutions.
By Eric Berger -
KHN’s ‘What the Health?’: On Capitol Hill, Actions Have Consequences
Several large business groups, including health industry organizations, are cutting off contributions to Republicans who voted against the certification of Joe Biden’s election even after riots shut down the Capitol on Jan. 6. Meanwhile, the outgoing Trump administration not only approved a Medicaid block grant for Tennessee, but also made it difficult for the incoming Biden administration to undo. Joanne Kenen of Politico, Margot Sanger-Katz of The New York Times and Kimberly Leonard of Business Insider join KHN’s Julie Rovner to discuss these issues and more. Plus, Rovner interviews KHN’s Victoria Knight about the latest KHN-NPR “Bill of the Month” episode.